MDGL

Company Overview — What Does MADRIGAL PHARMACEUTICALS, INC. Do?

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III clinical trials for the treatment of non-alcoholic steatohepatitis. The company also develops MGL-3745, a backup compound to resmetirom. It has research, development, and commercialization agreement with Hoffmann-La Roche. Madrigal Pharmaceuticals, Inc. is headquartered in West Conshohocken, Pennsylvania. MADRIGAL PHARMACEUTICALS, INC. (MDGL) is classified as a large-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO Paul A. Friedman and employs approximately 90 people, headquartered in WEST CONSHOHOCKEN, Pennsylvania. With a market capitalization of $12.2B, MDGL is one of the prominent companies in the Healthcare sector.

MADRIGAL PHARMACEUTICALS, INC. (MDGL) Stock Rating — Reduce (April 2026)

As of April 2026, MADRIGAL PHARMACEUTICALS, INC. receives a Reduce rating with a composite score of 32.1/100 and 2 out of 5 stars from the Blank Capital Research quantitative model.MDGL ranks #2,495 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, MADRIGAL PHARMACEUTICALS, INC. ranks #318 of 838 stocks, placing it in the upper half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

MDGL Stock Price and 52-Week Range

MADRIGAL PHARMACEUTICALS, INC. (MDGL) currently trades at $519.61. The stock lost $4.69 (0.9%) in the most recent trading session. The 52-week high for MDGL is $615.00, which means the stock is currently trading -15.5% from its annual peak. The 52-week low is $265.00, putting the stock 96.1% above its annual trough. Recent trading volume was 295K shares, suggesting relatively thin trading activity.

Is MDGL Overvalued or Undervalued? — Valuation Analysis

MADRIGAL PHARMACEUTICALS, INC. (MDGL) carries a value factor score of 31/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The price-to-book ratio stands at 19.48x, versus the sector average of 2.75x. The price-to-sales ratio is 16.79x, compared to 1.66x for the average Healthcare stock.

At current multiples, MADRIGAL PHARMACEUTICALS, INC. trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

MADRIGAL PHARMACEUTICALS, INC. Profitability — ROE, Margins, and Quality Score

MADRIGAL PHARMACEUTICALS, INC. (MDGL) earns a quality factor score of 20/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -55.9%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -26.7% versus the sector average of -33.1%.

On a margin basis, MADRIGAL PHARMACEUTICALS, INC. reports gross margins of 96.7%, compared to 71.5% for the sector. The operating margin is -76.7% (sector: -66.1%). Net profit margin stands at -71.3%, versus -58.7% for the average Healthcare stock. Revenue growth is running at 1862.5% on a trailing basis, compared to 10.6% for the sector. Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

MDGL Debt, Balance Sheet, and Financial Health

MADRIGAL PHARMACEUTICALS, INC. has a debt-to-equity ratio of 56.0%, compared to the Healthcare sector average of 32.0%. Leverage is within a manageable range for the industry, though investors should monitor debt trends over time. The current ratio is 4.01x, indicating strong short-term liquidity. Total debt on the balance sheet is $340M. Cash and equivalents stand at $296M.

MDGL has a beta of 0.61, meaning it is less volatile than the S&P 500, making it a relatively defensive holding. The stability factor score for MADRIGAL PHARMACEUTICALS, INC. is 58/100, reflecting average volatility within the normal range for its sector.

MADRIGAL PHARMACEUTICALS, INC. Revenue and Earnings History — Quarterly Trend

In TTM 2026, MADRIGAL PHARMACEUTICALS, INC. reported revenue of $699M and earnings per share (EPS) of $-12.85. Net income for the quarter was $-337M. Gross margin was 96.7%. Operating income came in at $-357M.

In FY 2025, MADRIGAL PHARMACEUTICALS, INC. reported revenue of $958M and earnings per share (EPS) of $-12.85. Net income for the quarter was $-288M. Revenue grew 432.1% year-over-year compared to FY 2024. Operating income came in at $-300M.

In Q3 2025, MADRIGAL PHARMACEUTICALS, INC. reported revenue of $287M and earnings per share (EPS) of $-5.08. Net income for the quarter was $-114M. Revenue grew 362.0% year-over-year compared to Q3 2024. Operating income came in at $-114M.

In Q2 2025, MADRIGAL PHARMACEUTICALS, INC. reported revenue of $213M and earnings per share (EPS) of $-1.90. Net income for the quarter was $-42M. Revenue grew 1353.8% year-over-year compared to Q2 2024. Operating income came in at $-47M.

Over the past 8 quarters, MADRIGAL PHARMACEUTICALS, INC. has demonstrated a growth trajectory, with revenue expanding from $15M to $699M. Investors analyzing MDGL stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

MDGL Dividend Yield and Income Analysis

MADRIGAL PHARMACEUTICALS, INC. (MDGL) does not currently pay a dividend. This is common among growth-oriented companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

MDGL Momentum and Technical Analysis Profile

MADRIGAL PHARMACEUTICALS, INC. (MDGL) has a momentum factor score of 54/100, reflecting neutral trend characteristics. The stock is neither significantly outperforming nor underperforming the broader market on a momentum basis. The investment factor score is 20/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 2/100 signals elevated short interest, which can indicate bearish sentiment among institutional investors.

MDGL vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, MADRIGAL PHARMACEUTICALS, INC. (MDGL) ranks #318 out of 838 stocks based on the Blank Capital composite score. This places MDGL in the upper half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing MDGL against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full MDGL vs S&P 500 (SPY) comparison to assess how MADRIGAL PHARMACEUTICALS, INC. stacks up against the broader market across all factor dimensions.

MDGL Next Earnings Date

No upcoming earnings date has been announced for MADRIGAL PHARMACEUTICALS, INC. (MDGL) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy MDGL? — Investment Thesis Summary

The quantitative profile for MADRIGAL PHARMACEUTICALS, INC. suggests caution. The quality score of 20/100 flags below-average profitability. The value score of 31/100 indicates premium valuation.

In summary, MADRIGAL PHARMACEUTICALS, INC. (MDGL) earns a Reduce rating with a composite score of 32.1/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on MDGL stock.

Related Resources for MDGL Investors

Explore more research and tools: MDGL vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare MDGL head-to-head with peers: MDGL vs AZN, MDGL vs SLGL, MDGL vs VMD.